TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38061370

Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once per day
Number of subjects: 13970

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13970
Study: 38061376

Group type: EXPERIMENTAL
Intervention: Three-drug nevirapine-based ART (cohort 1)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Three-drug nevirapine-based prophylaxis followed by three-drug nevirapine-based ART (cohort 2)
Number of subjects: 440
Study: 38061378

Group type: EXPERIMENTAL
Intervention: EUS-GE
Number of subjects: 97

Group type: COMPARATOR
Intervention: Duodenal stent
Number of subjects: 97
Study: 38061372

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6609
Study: 38061371

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6609
Study: 38061448

Group type: EXPERIMENTAL
Intervention: NIS2+™ pathway
Number of subjects: 1929

Group type: COMPARATOR
Intervention: FIB-4 pathway
Number of subjects: 1929

Group type: COMPARATOR
Intervention: RSP
Number of subjects: 1929
Study: 38061553

Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 77

Group type: COMPARATOR
Intervention: EMDR therapy and ST
Number of subjects: 77
Study: 38061630

Group type: EXPERIMENTAL
Intervention: Spiritual well-being
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: 12-step involvement
Number of subjects: 262

Group type: COMPARATOR
Intervention: Social support
Number of subjects: 262
Study: 38061681

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) for 4 days
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3)
Number of subjects: 95
Study: 38061786

Group type: EXPERIMENTAL
Intervention: Telehealth Mindfulness-Oriented Recovery Enhancement (MORE) plus usual care
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study: 38061976

Group type: EXPERIMENTAL
Intervention: Pelvic PSMA PET/CT
Number of subjects: 660

Group type: COMPARATOR
Intervention: Template transperineal prostate biopsies
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Avoidance of transperineal prostate biopsy
Number of subjects: 660
Study: 38062124

Group type: EXPERIMENTAL
Intervention: Induction therapy (IT) with novel agent-based triplet/quadruplet
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Risk score based on baseline factors
Number of subjects: 3700
Study: 38062132

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressings
Number of subjects: 689

Group type: COMPARATOR
Intervention: Petrolatum (control)
Number of subjects: 689
Study: 38062157

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for obesity for 8 weeks
Number of subjects: 45
Study: 38062221

Group type: EXPERIMENTAL
Intervention: LTBI-ASSIST Tool
Number of subjects: 130

Group type: COMPARATOR
Intervention: Guidelines only (Control)
Number of subjects: 130
Study: 38062421

Group type: EXPERIMENTAL
Intervention: SILS + 1
Number of subjects: 198

Group type: COMPARATOR
Intervention: CLS
Number of subjects: 198
Study: 38062475

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 10 weeks focusing on anxiety
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 90
Study: 38062732

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38062808

Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Number of subjects: 27
Study: 38063017

Group type: EXPERIMENTAL
Intervention: Ischemic stroke temporally associated with AF (ISTAF)
Number of subjects: 229565

Group type: COMPARATOR
Intervention: Patients without ischemic stroke
Number of subjects: 229565

Group type: COMPARATOR
Intervention: Patients with past ischemic stroke
Number of subjects: 229565
Study: 38063184

Group type: EXPERIMENTAL
Intervention: Manualised early rehabilitation and mobilisation intervention
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Paediatric Early Rehabilitation and Mobilisation during InTensive care manual
Number of subjects: 169
Study: 38063320

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 36
Study: 38063321

Group type: EXPERIMENTAL
Intervention: Elastic resistance strengthening
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional protocol
Number of subjects: 40
Study: 38063346

Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 2203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2203
Study: 38063930

Group type: EXPERIMENTAL
Intervention: Ultrasonographic optic nerve sheath diameter (ONSD) measurement on days 1-3
Number of subjects: 100

Group type: COMPARATOR
Intervention: EEG and SSEP (standard care)
Number of subjects: 100
Study: 38064141

Group type: EXPERIMENTAL
Intervention: Comprehensive CMR-based evaluation of LA size and function including LA length and LA reservoir strain.
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Comprehensive CMR-based evaluation of LA size and function.
Number of subjects: 648
Study: 38064153

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 38064219

Group type: EXPERIMENTAL
Intervention: Trauma Center Trauma-Sensitive Yoga (TCTSY) - 10 weekly, 60-minute group sessions
Number of subjects: 131

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT) - 12 weekly, 90-minute group sessions
Number of subjects: 131
Study: 38064241

Group type: EXPERIMENTAL
Intervention: 17q21 variants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38064260

Group type: EXPERIMENTAL
Intervention: S(+)-ketamine (0.3 mg/kg/h)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 38064262

Group type: EXPERIMENTAL
Intervention: Average daily steps (measured using Fitbit-HR Charge 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Average daily steps
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Step trajectories during treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Step trajectories early in the trial
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Step trajectories across the full duration of the trial
Number of subjects: 20
Study: 38064267

Group type: EXPERIMENTAL
Intervention: Secure Messaging Only (SM-Only)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Secure Messaging with Coaching (SM+Coach)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 53
Study: 38064268

Group type: EXPERIMENTAL
Intervention: Sit-to-stand video analysis-based app
Number of subjects: 686
Study: 38064454

Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiac shock wave therapy (ECSW) combined with optimal drug therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Optimal drug therapy
Number of subjects: 102
Study: 38064591

Group type: EXPERIMENTAL
Intervention: Pretreatment dual-phase contrast-enhanced cone-beam CT (CBCT) imaging
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Posttreatment 90Y PET/CT scan
Number of subjects: 9
Study: 38064972

Group type: EXPERIMENTAL
Intervention: 8-week virtual environment intervention
Number of subjects: 15
Study: 38065202

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study: 38065203

Group type: EXPERIMENTAL
Intervention: Sabatolimab plus hypomethylating agent (intravenous decitabine 20 mg/m2)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo plus hypomethylating agent (intravenous decitabine 20 mg/m2)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Sabatolimab plus hypomethylating agent
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo plus hypomethylating agent
Number of subjects: 127
Study: 38065200

Group type: EXPERIMENTAL
Intervention: Individualised open-lung approach (iOLA) ventilation strategy
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Standard lung-protective ventilation
Number of subjects: 1308
Study: 38065280

Group type: EXPERIMENTAL
Intervention: Telemedicine Enhanced Asthma Management through the Emergency Department (TEAM-ED)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: TEAM-ED (only prepandemic data)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Enhanced usual care (only prepandemic data)
Number of subjects: 373
Study: 38065326

Group type: EXPERIMENTAL
Intervention: LACbes device with no visible leak
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: LACbes device with residual device patency (RDP)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Presence of peri-device leak (PDL) at the lobe
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy after 6 months in patients with PDL at the lobe
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Maximum diameter of LAA orifice
Number of subjects: 141
Study: 38065403

Group type: EXPERIMENTAL
Intervention: Culturally tailored anti-smoking ads containing LGBTQ+ branding
Number of subjects: 2214

Group type: COMPARATOR
Intervention: Control ads without LGBTQ+ branding
Number of subjects: 2214
Study: 38065512

Group type: EXPERIMENTAL
Intervention: PillSense system (novel bleeding sensor)
Number of subjects: 126
Study: 38065906

Group type: EXPERIMENTAL
Intervention: CKD-495 75 mg
Number of subjects: 242

Group type: COMPARATOR
Intervention: AAF 60 mg
Number of subjects: 242
Study: 38066113

Group type: EXPERIMENTAL
Intervention: Cotadutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 0
Study: 38066442

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 10 cc sterile processed acellular hAF once daily for up to 5 days
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 38066454

Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin (PRF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Xenograft
Number of subjects: 36

Group type: COMPARATOR
Intervention: Alloplastic bone grafting material
Number of subjects: 36
Study: 38066459

Group type: EXPERIMENTAL
Intervention: Maximal isometric knee extension
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Maximal isometric hip abduction
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Handgrip strength
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Overall maximal isometric strength assessment
Number of subjects: 22
Study: 38066471

Group type: COMPARATOR
Intervention: Rectal microbicide modalities (douche, insert, suppository)
Number of subjects: 0
Study: 38066502

Group type: EXPERIMENTAL
Intervention: New Families home visiting program
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Appraisal support
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: QoL levels in pregnancy
Number of subjects: 228
Study: 38066522

Group type: EXPERIMENTAL
Intervention: anti-PD-1 immunotherapy
Number of subjects: 54
Study: 38066564

Group type: EXPERIMENTAL
Intervention: AT101 (h1218-CART19)
Number of subjects: 12
Study: 38066597

Group type: EXPERIMENTAL
Intervention: Exenatide (once weekly) plus standard treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (standard treatment alone)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Exenatide group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 38066614

Group type: EXPERIMENTAL
Intervention: Remote consultation (teleconsultation or video consultation)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Conventional face-to-face consultation (control)
Number of subjects: 1068
Study: 38066613

Group type: EXPERIMENTAL
Intervention: Subclass 1 (patients with septic shock)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Subclass 2 (patients with septic shock)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Noninfected controls without shock
Number of subjects: 98
Study: 38066644

Group type: EXPERIMENTAL
Intervention: Somapacitan (0.16 mg/kg/week)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Daily GH (0.034 mg/kg/day)
Number of subjects: 128
Study: 38066658

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 70
Study: 38067150

Group type: EXPERIMENTAL
Intervention: IL-6 protein levels of ≥6.4 pg/mL
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Genetic variants (rs1800795, rs1800797)
Number of subjects: 1002
Study: 38067353

Group type: EXPERIMENTAL
Intervention: Machine-learning models incorporating CT imaging features
Number of subjects: 255
Study: 38068424

Group type: EXPERIMENTAL
Intervention: Vojta therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38068820

Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 12
Study: 38068830

Group type: EXPERIMENTAL
Intervention: Meal photographs paired with traditional food records using the Bitesnap app.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Automated Self-Administered 24-h Dietary Assessment Tool (ASA24) for food records.
Number of subjects: 110
Study: 38069986

Group type: EXPERIMENTAL
Intervention: TricValve system
Number of subjects: 44
Study: 38070031

Group type: EXPERIMENTAL
Intervention: IFNβ-1a plus 2 gm of metformin once daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: IFNβ-1a alone
Number of subjects: 80
Study: 38070039

Group type: EXPERIMENTAL
Intervention: Safinamide as add-on to levodopa
Number of subjects: 854

Group type: COMPARATOR
Intervention: Placebo as add-on to levodopa
Number of subjects: 854
Study: 38070132

Group type: EXPERIMENTAL
Intervention: Increased sleep duration (IN) for 1 week (1 hour 30 min/night increase)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Habitual sleep (HB) for 1 week
Number of subjects: 43

Group type: COMPARATOR
Intervention: Decreased sleep (DE) for 1 week (1 hour 19 min/night decrease)
Number of subjects: 43
Study: 38070147

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 44
Study: 38070159

Group type: EXPERIMENTAL
Intervention: pembrolizumab plus chemotherapy
Number of subjects: 317

Group type: COMPARATOR
Intervention: placebo plus chemotherapy
Number of subjects: 317
Study: 38070309

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral nerve block performed by specially trained nurses (Group Nurse)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ultrasound-guided femoral nerve block performed by anaesthesiologists (Group Anaesthesiologist)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nurse Group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Anaesthesiologist Group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 38070597

Group type: EXPERIMENTAL
Intervention: Neoadjuvant atezolizumab
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Visual determination of percent viable tumor
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Digitally assessed percent viable tumor
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Digitally assessed major PathR
Number of subjects: 151
Study: 38070635

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors (alirocumab 150 mg sc or evolocumab 140 mg sc every two weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 38070683

Group type: EXPERIMENTAL
Intervention: Cocoa extract (CE) 500 mg flavanols/d, including 80 mg (-)-epicatechin
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Cocoa extract (CE)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study: 38070682

Group type: EXPERIMENTAL
Intervention: Folic acid-containing supplements during treatment
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Folic acid in plasma at diagnosis
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Folic acid in plasma during treatment
Number of subjects: 290
Study: 38070868

Group type: EXPERIMENTAL
Intervention: Leadership and Organizational Change for Implementation strategy plus training and technical assistance in MBC
Number of subjects: 234

Group type: COMPARATOR
Intervention: Training and technical assistance only
Number of subjects: 234
Study: 38070883

Group type: EXPERIMENTAL
Intervention: Cabrol shunt
Number of subjects: 3283

Group type: COMPARATOR
Intervention: Non-Cabrol shunt
Number of subjects: 3283

Group type: EXPERIMENTAL
Intervention: Cabrol shunt (without root replacement)
Number of subjects: 3283

Group type: EXPERIMENTAL
Intervention: Cabrol shunt (with root replacement)
Number of subjects: 3283
Study: 38070892

Group type: EXPERIMENTAL
Intervention: COVID-19 cases
Number of subjects: 3860

Group type: COMPARATOR
Intervention: Population controls
Number of subjects: 3860

Group type: EXPERIMENTAL
Intervention: Vaccination status
Number of subjects: 3860

Group type: EXPERIMENTAL
Intervention: Household contacts
Number of subjects: 3860

Group type: EXPERIMENTAL
Intervention: Antibody levels
Number of subjects: 3860

Group type: EXPERIMENTAL
Intervention: Long-COVID impact
Number of subjects: 3860
Study: 38070890

Group type: EXPERIMENTAL
Intervention: Random forest and multivariable logistic regression for predicting incident AF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher predicted risk of AF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower predicted risk of AF
Number of subjects: 0
Study: 38070895

Group type: EXPERIMENTAL
Intervention: Nutritional ultrasound (muscle US) techniques
Number of subjects: 1000
Study: 38070904

Group type: EXPERIMENTAL
Intervention: Current criteria for VAP surveillance in Brazil
Number of subjects: 0

Group type: COMPARATOR
Intervention: CDC-defined VAE criteria
Number of subjects: 0
Study: 38070906

Group type: EXPERIMENTAL
Intervention: GnRHa (triptorelin)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 38070914

Group type: EXPERIMENTAL
Intervention: Rockwood Clinical Frailty Scale (CFS)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Frail NonDisabled Questionnaire
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Healthcare Improvement Scotland FRAIL tool
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Initial Clinical Evaluation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 11-item modified Frailty Index
Number of subjects: 2

Group type: COMPARATOR
Intervention: Surgical procedure
Number of subjects: 2

Group type: COMPARATOR
Intervention: Prognostic value comparison
Number of subjects: 2

Group type: COMPARATOR
Intervention: Continuous outcome variables analysis
Number of subjects: 2

Group type: COMPARATOR
Intervention: Interuser agreement comparison
Number of subjects: 2
Study: 38070920

Group type: EXPERIMENTAL
Intervention: Thrombectomy using Neurohawk or Solitaire FR
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Thrombectomy with ICA occlusion
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Thrombectomy with initial NIHSS score ≥17
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Thrombectomy with final mTICI score 2b
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Thrombectomy with more than one pass
Number of subjects: 207
Study: 38070921

Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 210
Study: 38070928

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo cryotherapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups (WBC and placebo)
Number of subjects: 56
Study: 38071300

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 19
Study: 38071379

Group type: EXPERIMENTAL
Intervention: Tislelizumab plus zanubrutinib for 12 cycles
Number of subjects: 48
Study: 38071422

Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg twice daily (b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maribavir (400, 800, or 1200 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 0
Study: 38071462

Group type: EXPERIMENTAL
Intervention: Ziritaxestat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziritaxestat on top of pirfenidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziritaxestat on top of nintedanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziritaxestat alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPA C18:2 reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATX concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction in LPA C18:2
Number of subjects: 0
Study: 38071574

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 732

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 732
Study: 38071986

Group type: EXPERIMENTAL
Intervention: Reduction group (ICS-formoterol dose tapering)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Reduction group
Number of subjects: 208

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 208
Study: 38071990

Group type: EXPERIMENTAL
Intervention: SIM01 (10 billion colony-forming units in sachets twice daily)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study: 38071994

Group type: EXPERIMENTAL
Intervention: Transitional Community Adherence Club (TCAC)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Usual care (passive referral)
Number of subjects: 176
Study: 38072156

Group type: EXPERIMENTAL
Intervention: LEAPS intervention (center-based ECCE program)
Number of subjects: 3858
Study: 38072158

Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg intravenously every 3 weeks for ≤93 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 54
Study: 38072183

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (2800 IU/d)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standard dose vitamin D3 (400 IU/d)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Maternal preintervention 25(OH)D levels
Number of subjects: 700